http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 May 2024 02:20:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Press+Releases/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Business+Wire/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Business+Wire/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Business+Wire/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Business+Wire/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI http://www.streetinsider.com/Business+Wire/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html si-local-file:///var/storage/newsbody/2021/0114/17821228.html http://www.streetinsider.com/Business+Wire/ONK+Therapeutics+Appoints+Hugh+O%E2%80%99Dowd+as+Independent+Chairman/17821228.html Thu, 14 Jan 2021 03:00:00 -0400 A.00504526 A.07261051 A.30921872 A.38263367 NTGN PBYI